Therapeutic effects of ML-236B in primary hypercholesterolemia

Citations of this article
Mendeley users who have this article in their library.


ML-23613, a competitive inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase, was administered to 11 patients with primary hypercholesterolemia. After 4-8 weeks of drug treatment at doses of 50-150 mg/day, serum cholesterol levels were reduced by 11-37% (27% on average) in cases of heterozygous familial hypercholesterolemia and combined hyperlipidemia. A marked reduction in tuberous xanthomas was noticed in a homozygous case of familial hypercholesterolemia, but here the drug was less effective in reducing the serum cholesterol level and a higher dose was required for treatment. Softening of Achilles tendon xanthomas was observed in a case of combined hyperlipidemia. © 1980.




Yamamoto, A., Sudo, H., & Endo, A. (1980). Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis, 35(3), 259–266.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free